13/04/2026 Saphnelo® subcutaneous approved in Canada for the treatment of SLE Saphnelo® subcutaneous approved in Canada for the treatment of SLE ( Ref ) Astrazeneca announced that Health Canada had granted a Notice of Compliance (NOC) for Saphnelo ®  (anifrolumab; type 1 IFNR) for subcutaneous self-administration via a single-use autoinjector in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) in addition to standard therapy The approval by

19/02/2026 AstraZeneca’s Saphnero was approved in Japan for patients with Systemic Lupus Erythematosus AstraZeneca’s Saphnero was approved in Japan for patients with Systemic Lupus Erythematosus ( Ref ) AstraZeneca announced that Japan had approved Saphnero (aniflorumab; anti-IFN1R) subcutaneous injection 120 mg autoinjector for the treatment of patients with Systemic Lupus Erythematosus (SLE) This approval by the Ministry of Health, Labour and Welfare was based on the result